Dana Farber-Merrimack Valley

Summary

Dana Farber-Merrimack Valley is a medical facility located in Methuen, Massachusetts. This center is recognized for care of Lung Cancer, Non-Small Cell Lung Cancer, Breast Cancer, Breast cancer, Colon Cancer and other specialties. Dana Farber-Merrimack Valley is involved with conducting 11 clinical trials across 21 conditions. There are 2 research doctors associated with this hospital, such as Pedro M. Sanz-Altamira and Taylor M. Ortiz.

Top PIs

Clinical Trials running at Dana Farber-Merrimack Valley

Lung Cancer

Esophageal cancer

Kidney Cancer

Non-Small Cell Lung Cancer

Prostate Cancer

Renal Cell Carcinoma

Breast Cancer

Breast cancer

Esophageal Adenocarcinoma

Gastric cancer

Chemotherapy + Immunotherapy vs. Immunotherapy

for Advanced Lung Cancer

This phase III trial compares the effect of adding chemotherapy to immunotherapy (pembrolizumab) versus immunotherapy alone in treating patients with stage IIIB-IV lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab and chemotherapy may help stabilize lung cancer.

Recruiting

2 awards

Phase 3

Immunotherapy + Chemotherapy

for Non-Small Cell Lung Cancer

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.

Recruiting

2 awards

Phase 3

27 criteria